EGFR and neoplasm: Strikingly, deletion of EGFR exon 19 and a point mutation in exon 21 account for up to 90% of EGFR mutations in the clinic and correspond to two distinct tumour subtypes with different clinical characteristics and response to EGFR tyrosine kinase inhibitors [11, 12].